TRAIL-Dependent Resolution of Pulmonary Fibrosis

Figure 6

Altered TRAIL and DR5 expression in plasma, whole lung tissues, and primary fibroblasts from IPF patients. (a–f) Lung biopsies were obtained from nonfibrotic disease or IPF patients, fixed, paraffin-embedded, sectioned, and stained for TRAIL, DR5, or CD33. (a, c, e) Normal lungs stained for TRAIL, DR5, and CD33, respectively. (b, d, f) IPF lungs stained for TRAIL, DR5, and CD33, respectively. Statistical analysis were performed using ordinary one-way ANOVA test; . (g) Plasma was collected from normal volunteers and IPF patients and ELISA was used to determine soluble TRAIL concentrations. (h) Lung fibroblasts were purified from nonfibrotic or IPF lung biopsies. Fibroblasts were left untreated or treated 10 ng/ml of IL-13 for 24 h. Quantitative PCR was used to determine the expression of TRAIL and DR5. Data are mean ± SEM, n = 3–5 independent experiments.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)